Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Good safety and pharmacokinetic profile reported for rhFXIII in healthy volunteers

July 21, 2003

Antithrombotic effects described for PAR-1 antagonist in guinea pig model

July 18, 2003

Potent, selective and orally active thrombin inhibitor in development at Servier

July 18, 2003

Pharmacodynamics and pharmacokinetics of C3 and RO-14 in monkeys

July 18, 2003

CS-747 prevents cerebral and peripheral arterial occlusive diseases in rats

July 18, 2003

Effective inhibition of thrombosis and moderate hemorrhage risk with melagatran in baboons

July 17, 2003

H3 Pharma acquires rights to vapreotide from Debiopharm

July 17, 2003

Factor Xa inhibitors and their application described by Lilly

July 10, 2003

Activated recombinant factor VII may improve bleeding control in cirrhosis

July 10, 2003

BMS researchers present new compounds with factor VIIa/IMPDH-inhibitory activity

July 8, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 27, 2026.
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Daybu readthrough in EU? Zevra’s NPC bid flounders
BioWorld
Zevra Therapeutics Inc. will try to follow in the footsteps of Acadia Pharmaceuticals Inc. with Rett syndrome drug Daybu (trofinetide) by asking the EMA’s...
Transcripta Bio raises funding to advance neuro pipeline
BioWorld Science
Transcripta Bio Inc. has raised $24 million since its series A to fund IND-enabling studies across its portfolio and support clinical preparation in its autism...